New Drug Development Status
| Development Code | Planned Indication | Development Stage | Notes |
|---|---|---|---|
| KAR | Head lice | Phase Ⅲ | In-licensed from Arbor Pharmaceuticals, LLC. Product name in the US: Sklice |
| KP-001 (ART-001) |
Refractory vascular malformations | Phase Ⅲ | Development project succeeded from ARTham Therapeutics Inc. |
| BBI-4000 | Primary palmoplantar hyperhidrosis | Phase Ⅰ | Additional indication of Ecclock |
| KP-483 | Solid tumors (immuno-oncology) |
Phase Ⅰ | In-house discovered product |
| NM26-2198 | Atopic dermatitis | Phase Ⅰ | Co-development with Numab Therapeutics AG |
| KP-910 | Peripheral neuropathic pain | Phase Ⅰ | In-house discovered product |
| Seladelpar | Primary biliary cholangitis | Phase Ⅰ | In-licensed from CymaBay Therapeutics, Inc. |
| Tildacerfont | Congenital adrenal hyperplasia | Phase Ⅰ | In-licensed from Spruce Biosciences, Inc. |